DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos Sells 3,672 Shares

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director now directly owns 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Nicholas Augustinos also recently made the following trade(s):

• On Friday, June 13th, Nicholas Augustinos sold 2,618 shares of DexCom stock. The stock was sold at an average price of $81.69, for a total value of $213,864.42.

DexCom Price Performance

DXCM stock traded down $1.17 during trading on Tuesday, hitting $81.83. The stock had a trading volume of 2,685,622 shares, compared to its average volume of 4,343,966. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.49. The company's 50-day moving average price is $78.95 and its two-hundred day moving average price is $79.36. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The stock has a market capitalization of $32.09 billion, a P/E ratio of 61.07, a PEG ratio of 1.77 and a beta of 1.46.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the company earned $0.32 EPS. DexCom's quarterly revenue was up 12.5% compared to the same quarter last year. As a group, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DXCM shares. Citigroup reissued a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Piper Sandler dropped their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. The Goldman Sachs Group assumed coverage on shares of DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price target on the stock. Finally, Barclays lifted their price objective on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

Institutional Trading of DexCom

Several large investors have recently added to or reduced their stakes in DXCM. Private Trust Co. NA grew its position in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the period. Golden State Wealth Management LLC lifted its position in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in DexCom in the first quarter valued at $27,000. Optiver Holding B.V. purchased a new position in DexCom in the fourth quarter worth approximately $33,000. Finally, TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.